Astrazeneca Pharma India Ltd Share Price – NSE /  BSE

Pharmaceuticals, Small Cap

Astrazeneca Pharma India announced that the Board of Directors of the Company at its meeting held on 26 May 2026, inter alia, have recommended the final dividend of Rs 36 per equity Share (i.e. 1800%) , subject to the approval of the shareholders.

Net profit of Astrazeneca Pharma India declined 22.95% to Rs 44.88 crore in the quarter ended March 2026 as against Rs 58.25 crore during the previous quarter ended March 2025. Sales rose 20.42% to Rs 578.61 crore in the quarter ended March 2026 as against Rs 480.48 crore during the previous quarter ended March 2025.

For the full year,net profit rose 62.02% to Rs 187.52 crore in the year ended March 2026 as against Rs 115.74 crore during the previous year ended March 2025. Sales rose 32.59% to Rs 2275.58 crore in the year ended March 2026 as against Rs 1716.29 crore during the previous year ended March 2025.

Powered by Capital Market - Live News

Astrazeneca Pharma India will hold a meeting of the Board of Directors of the Company on 26 May 2026.

Through this approval, Acalabrutinib tablets 100 mg in combination with venetoclax with or without obinutuzumab is indicated for the treatment of patients with previously untreated chronic lymphocytic leukaemia (CLL) /small lymphocytic lymphoma (SLL).

This regulatory clearance paves the way for the commercial launch and availability of Calquence in the Indian market.

AstraZeneca is a global biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines in four areas: Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Rare Diseases. It operates in over 100 countries.

The company?s standalone net profit declined 42.3% to Rs 31.55 crore despite 38.9% increase in net sales to Rs 615.57 crore in Q3 FY26 over Q3 FY25.

The counter advanced 1.45% to end at Rs 8,291.50 on Friday, 10 April 2026.